VRDN Q4 2018 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$476,000-60.1% YoY

Gross Profit

-$8M-1629.8% margin

Operating Income

-$10M-2196.0% margin

Net Income

-$10M-2167.4% margin

EPS (Diluted)

$-5.02

QoQ Revenue Growth

-49.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$937,000

Balance Sheet

Total Assets

$66M

Total Liabilities

$15M

Stockholders' Equity

$51M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$476,000	$1M	-60.1%
Gross Profit	-$8M	-$4M	-103.8%
Operating Income	-$10M	-$6M	-64.5%
Net Income	-$10M	-$6M	-61.6%

Revenue Segments

Collaboration Revenue

$435,00050%

Reimbursement Revenue

$435,00050%